What We Do

Pharmaceutical QMS Advisory Services

Specialized expertise across the full spectrum of pharmaceutical quality management — from post-inspection remediation to building robust, inspection-ready quality systems.

Focused on pharmaceutical industry with aseptic processes · FDA & EU regulatory frameworks

QMS Remediation Programs

Turning inspection findings into lasting compliance

FDA 21 CFR Parts 210/211EU GMP Annex 1ICH Q10ICH Q9

Following an FDA or EU inspection, the path from findings to sustained compliance requires more than a written response — it demands a structured, evidence-based remediation program. We design and implement holistic remediation plans that address root causes, not just symptoms.

What we deliver

Gap assessment against FDA 21 CFR and EU GMP requirements
Prioritized remediation roadmap with timelines and ownership
CAPA development and implementation oversight
Effectiveness monitoring and KPI frameworks
Pre-submission review of remediation evidence packages

FDA 483 & Warning Letter Response

Expert responses that demonstrate credible commitment to compliance

FDA 21 CFR Parts 210/211FDA Warning Letter guidanceCDER/CBER inspection programs

A poorly structured 483 response or Warning Letter reply can escalate regulatory scrutiny. Our advisors have deep experience preparing responses that are factually precise, regulatory-grade in language, and backed by credible corrective action commitments that satisfy FDA reviewers.

What we deliver

Analysis of each observation and its regulatory basis
Drafting of 483 responses with immediate and long-term corrective actions
Warning Letter response preparation and review
CAPA development aligned with FDA expectations
Follow-up correspondence and commitment tracking

Inspection Response & Audit Readiness

Prepared for every inspector, every time

EU GMP Annex 1 (Aseptic Manufacturing)FDA Guidance for Industry: Sterile Drug ProductsPIC/S PE 009

Inspection readiness is not a one-time event — it is a continuous state of operational excellence. We prepare pharmaceutical manufacturers for FDA and EU GMP inspections through structured readiness programs, mock audits, and real-time support during and after inspections.

What we deliver

Pre-inspection readiness assessments and gap analysis
Mock FDA and EU GMP inspections with detailed findings reports
Inspection response strategy and back-room support
Preparation of responses to EU inspection findings
Aseptic process and sterile manufacturing inspection focus

CAPA Development & Implementation

Root cause analysis that eliminates recurrence

ICH Q10 Pharmaceutical Quality SystemFDA 21 CFR 211.192EU GMP Chapter 1

Effective CAPAs require rigorous root cause analysis, not just corrective actions that satisfy the immediate finding. We develop CAPAs that address systemic causes, are proportionate to risk, and include effectiveness checks that demonstrate sustained compliance to regulators.

What we deliver

Structured root cause analysis (Ishikawa, 5-Why, fault tree)
CAPA development with immediate, short-term, and long-term actions
Implementation oversight and milestone tracking
Effectiveness monitoring protocols and metrics
CAPA closure packages for regulatory submission

Quality System Audits

Independent assessment against FDA and EU standards

EU GMP Parts I & IIFDA 21 CFR Parts 210/211/820ISO 13485Annex 1 (2022)

Our quality system audits provide an independent, expert assessment of your QMS against current FDA and EU GMP requirements. Conducted by advisors with direct regulatory experience, our audits identify gaps before regulators do — and provide a clear path to remediation.

What we deliver

Full QMS audit against EU GMP and FDA 21 CFR requirements
Aseptic process and sterile manufacturing audit focus
Detailed findings report with regulatory citations
Risk-ranked gap analysis and remediation priorities
Executive summary for senior management and board reporting

SOP & Technical Document Translation

Regulatory-grade English for global submissions

FDA submission language requirementsEMA translation guidelinesICH Common Technical Document (CTD)

Regulatory submissions, inspection responses, and technical reports must be precise in language as well as content. We provide expert translation of SOPs, technical reports, and regulatory correspondence into English — by advisors who understand both the regulatory context and the technical subject matter.

What we deliver

Translation of Standard Operating Procedures (SOPs) into English
Translation of technical reports and validation documents
Translation of inspection responses and regulatory correspondence
Regulatory terminology review and consistency checks
Bilingual document formatting for dual-language submissions

Robust Quality System Design

Building quality systems that sustain compliance

ICH Q10 Pharmaceutical Quality SystemFDA Quality Metrics guidanceEU GMP Chapter 1 & Annex 1

Beyond remediation, we help pharmaceutical manufacturers build quality systems that are inherently robust — designed to prevent failures, detect deviations early, and demonstrate a culture of quality to regulators. Our holistic programs address governance, procedures, training, and metrics.

What we deliver

Quality system architecture and governance framework design
SOP development, harmonization, and lifecycle management
Quality metrics and KPI dashboard design
Training program development and competency frameworks
Management review and quality council program design

Specialist Focus

Aseptic Process Expertise

Our advisory practice has deep specialization in aseptic manufacturing — one of the highest-risk and most heavily scrutinized areas of pharmaceutical production. From Annex 1 (2022) implementation to sterile process validation, we bring direct experience with the regulatory expectations that govern aseptic operations.

Aseptic advisory areas

Annex 1 (2022) gap assessment and implementation
Aseptic process simulation (media fill) programs
Environmental monitoring program design
Contamination control strategy development
Sterile process validation and qualification

Not sure which service fits your situation?

Most engagements begin with a confidential consultation where we assess your specific regulatory situation and recommend the right advisory approach.

Schedule a Consultation